CNMD

CONMED Corp. 10-Q Summary: Period Ended September 30, 2005

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2005, and the nine-month period ended on that date. CONMED Corporation is a medical technology company specializing in instruments, implants, and video equipment for arthroscopic sports medicine, powered surgical instruments, radio frequency electrosurgery systems, endosurgery products, and patient care products. The company operates through five principal units aggregated into a single segment. A significant portion of revenue (36.9% for the nine months) is derived from international sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.4% ($17.7 million) for the quarter and 16.8% ($66.9 million) for the nine months compared to the prior year. The Bard Endoscopic Technologies acquisition accounted for $15.2 million of the quarterly increase and $44.4 million of the nine-month increase.
• Profitability: Net income for the quarter rose significantly from $1.7 million to $7.9 million. This improvement is largely due to the absence of a $13.7 million write-off of purchased in-process research and development (IPR&D) assets recorded in the same quarter of 2004.
• Expense Increases: Selling and administrative expenses increased 23.0% for the quarter, driven by litigation costs (Johnson & Johnson antitrust suit), higher distribution costs, and increased pension expenses due to actuarial assumption changes. R&D expenses increased 36.2% for the quarter due to the Bard acquisition and new product development (Pro2).
• Margin Compression: Gross margins decreased slightly (51.0% to 50.6% for the quarter) due to $1.8 million in acquisition-related charges associated with the Bard transition agreement.

Guidance, Outlook, and Risks

• Acquisition Integration: The company is transitioning manufacturing of Bard Endoscopic Technologies products from C.R. Bard facilities to CONMED facilities, expected to be completed in 2006. Costs associated with this transition are currently higher than long-term expectations.
• Legal Proceedings: CONMED is engaged in antitrust litigation against Johnson & Johnson. While management believes the claims are well-grounded, there is no assurance of success, and costs may be material. The company also settled environmental claims in Q2 2005 for approximately $0.7 million.
• Product Line Termination: The company is terminating its surgical lights product line. A replacement program is underway with total expected costs of $5.8 million; $2.3 million of these costs are anticipated to be incurred in late 2005 and early 2006.
• Capital Allocation: The company plans to repurchase an additional $4.0 million of common stock in the fourth quarter to offset dilution from employee stock plans. Capital expenditures for the full year 2005 are expected to approximate $15.0 million.
• Accounting Changes: The company is evaluating the impact of SFAS 123R (Share-Based Payment), required to be adopted by January 1, 2006, which will likely increase reported expenses.

Investor Verification Checklist

• Acquisition Synergies: Verify the timeline and cost savings realization for the Bard Endoscopic Technologies manufacturing transition scheduled for completion in 2006.
• Legal Exposure: Monitor the status of the antitrust lawsuit against Johnson & Johnson and the potential for summary judgment or settlement costs.
• Inventory Levels: Review the increase in inventory ($152.3 million vs. $127.9 million prior year-end) to ensure it aligns with the transition of Bard products and does not indicate obsolescence risks.
• Debt Service: Confirm the company's ability to meet scheduled principal payments on the term loan ($2.6 million annually through 2007) and the $150 million convertible notes due in 2024.
• Stock Repurchase Program: Track the execution of the remaining $37.2 million authorized under the share repurchase program.